The 3–6 month window — and why it exists

Three to six months. That is the consistently cited conservative trial window for a talar osteochondral lesion (OLT), drawn from multiple systematic reviews including Bruns (2021), Lan (2021), and Wang (2020). The figure is not an arbitrary patience threshold — it reflects a structured, two-phase clinical programme with specific biological and functional goals at each stage.

The two phases are distinct and sequential. The first four to eight weeks involve protected weight-bearing in a CAM boot or short-leg cast, often on crutches, to offload the damaged talar cartilage and allow subchondral bone marrow oedema to settle. This phase must precede any meaningful physiotherapy; beginning loading exercises too early undermines the biological rationale. The physiotherapy phase that follows — typically six to twelve weeks — then targets the functional deficits created by the immobilisation period.

The trial also carries a diagnostic function. By running a full conservative programme before any surgical planning, clinicians identify which patients can recover without intervention — a distinction that cannot reliably be made from imaging alone. Treating the window as a structured clinical programme rather than a holding period translates directly into better adherence and more reliable data for the referral decision that may follow.

Phase one: why immobilisation comes before physio

Talar cartilage has no direct blood supply — it depends on diffusion from synovial fluid and from the subchondral bone beneath it. When that subchondral layer is inflamed and oedematous, the nutritional exchange is compromised, and repeated mechanical loading perpetuates the cycle. The offloading phase breaks it: removing weight from the joint long enough for the bone marrow oedema to settle restores the biological environment in which cartilage repair can begin.

Cast durations vary across published programmes — the Buck (2023) systematic review found immobilisation periods ranging from three to eight weeks across 30 studies. The exact duration is set by the treating clinician, based on lesion size, imaging findings, and how symptoms are responding. There is no single fixed protocol.

For patients, six to eight weeks on crutches can feel like a pause before treatment starts. It is not — the biology is actively changing during this period. Starting strengthening or weight-bearing exercises before bone marrow oedema has settled does not accelerate recovery; it forfeits the protective rationale the whole programme depends on. Phase one is clinical management, not waiting.

Phase two: what the physiotherapy programme actually targets

The three rehabilitation goals in phase two are well established across physiotherapy practice, even if the specific exercise prescriptions vary between practitioners — Buck (2023) supports the 3–6 month conservative window robustly, but no single protocol has been tested head-to-head in a controlled trial. The goals are consistent; the exact exercises are not fixed.

Peroneal and calf strengthening

The peroneal muscles run along the outer ankle and act as its primary dynamic stabilisers. For a talar cartilage defect the relevance is specific: weakness here allows excessive inversion during gait, generating shear forces across the talar dome at the precise site of the lesion. Reducing that shear load is the target — not general ankle strength for its own sake.

Proprioception and neuromuscular control

Weeks in a boot blunt joint position sense measurably. Single-leg stance, wobble board progressions, and graded plyometrics rebuild the neuromuscular feedback loop that allows the ankle to respond to uneven ground automatically — reducing the peak loads the cartilage must absorb on each step.

Range of motion

Dorsiflexion in particular stiffens during immobilisation, and recovering it is a clinical priority rather than a flexibility add-on. Restricted dorsiflexion forces compensatory movement patterns at the subtalar joint and knee, altering load distribution across the ankle in ways that can worsen symptoms after the boot comes off.

How consistently a patient engages with their programme determines what the phase actually delivers. The goals are the same for everyone; the outcome is not.

Realistic outcomes: what conservative management can and cannot achieve

The Buck (2023) systematic review — 30 studies, 868 patients, median follow-up 37 months — places the pooled clinical success rate for non-operative OLT management at 45% (95% CI 40–50%). The orthobiologics literature rounds this to approximately 50%. Both figures point in the same direction.

The framing is important: roughly half of patients who complete the full conservative course will not achieve a satisfactory outcome. That is not a treatment failure — it is the expected referral pathway. The 3–6 month window exists precisely to identify which half a patient falls into before surgery becomes the appropriate conversation. Knowing this early is clinically useful, not discouraging.

For patients weighing whether to commit to the trial, the radiological data from Buck (2023) is reassuring. Focal OLT deterioration was observed in approximately 11% of patients on CT and 12% on MRI during conservative management; ankle osteoarthritis progression on plain radiograph appeared in approximately 9%. The majority completing the conservative window do not worsen structurally in ways that close down later options. Completing the trial, for most patients, does not burn bridges.

What this means in practice: a patient who engages fully with the programme and still has significant, function-limiting ankle pain at the six-month mark is not experiencing an unusual outcome — they are a candidate for specialist escalation, as the evidence anticipated from the outset.

Lesion features that shorten — or skip — the conservative window

Not every talar cartilage lesion should follow the same timeline. Several imaging and clinical features modify the 3–6 month default — some by shortening it, some by prompting an earlier specialist conversation before physiotherapy has even begun.

Lesion characteristics that support the full trial

The strongest candidates for completing the full conservative window are lesions under 10 mm in diameter that sit intact beneath an undisturbed cartilage surface — what the Berndt and Harty staging system classifies as Stage I (bone bruise, cartilage intact) or Stage II (partial cartilage separation, fragment still in place). For these, the biological rationale for conservative care is sound and the evidence supports giving it the full 3–6 months.

Features that warrant earlier specialist input

Several imaging characteristics suggest the conservative window is unlikely to succeed and that earlier specialist review is appropriate:

• Lesion diameter exceeding 15 mm — larger defects have a reduced capacity for spontaneous repair and are generally considered surgical territory
• Cystic lesions — subchondral cyst formation indicates deeper bone involvement that loading-modification and exercise cannot address
• Deep subchondral involvement beyond 7 mm — depth compounds the structural instability of the lesion
• Stage III or IV lesions — a displaced or completely detached fragment is unlikely to reduce and stabilise through physiotherapy alone

These features are typically visible on MRI, which is why a plain radiograph alone may give an incomplete picture. If the initial imaging was X-ray only, MRI findings can change the clinical plan substantially — and early specialist input helps interpret them in context.

Symptom-based red flags

Regardless of what imaging shows, certain symptoms justify earlier escalation: a sensation of the ankle locking, catching, or a loose body moving within the joint suggests mechanical instability that physiotherapy cannot resolve. These are clinical signs, not imaging findings — they can be present even when a lesion appears contained on MRI.

For patients with smaller, stable lesions and no mechanical symptoms, the full conservative trial remains the appropriate and well-supported starting point.

What a cartilage specialist assessment involves — and what comes next

Arriving at a cartilage specialist after six months of conservative management means the assessment picks up where the physiotherapy programme left off. The clinician will review the full symptom timeline, prior imaging, and may request updated MRI if existing scans are more than six months old. A mechanical examination of the ankle follows — joint stability, range of motion, weight-bearing tolerance under load — with the aim of classifying the defect precisely: size, depth, cystic involvement, and cartilage surface integrity together determine what comes next.

For smaller, contained defects where conservative care has fallen short, the next tier of options includes extended physiotherapy with biologic support such as platelet-rich plasma (PRP), or an injectable collagen scaffold. ChondroFiller injection — delivered as an ultrasound-guided outpatient procedure — places a matrix directly into the defect to recruit the patient's own progenitor cells, without theatre, general anaesthesia, or the rehabilitation demands associated with open cartilage surgery.

Larger, deeper, or cystic lesions may require arthroscopic bone marrow stimulation (microfracture or drilling), osteochondral autograft transfer (OATS), or autologous chondrocyte implantation, each carrying more substantial recovery timelines.

In the UK, ChondroFiller injection for eligible talar defects is available at the London Cartilage Clinic on Harley Street, the UK certified centre for this treatment pathway.